With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).
SE announced earlier that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La ...
Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq ... provide an update after each capital increase on a dedicated location on its corporate website in order to inform investors ...
Valneva also has an ongoing license agreement with the Serum Institute of India (SII) to supply its vaccine at an affordable ...
Saint-Herblain (France), March 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its consolidated financial results for the year ended ...
Valneva SE, a specialty vaccine company, announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine Ixchiq. In agreement ...
Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal ...
Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces that it has filed a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback